argenx NV ADR

Yahoo Finance • 4 months ago

Jefferies Group Amplifies S&P 500 ETF Trust Holdings in Q2 2024

Insightful Portfolio Adjustments Highlight Strategic Market Moves Jefferies Group (Trades, Portfolio), under the leadership of CEO Richard Handler since the acquisition of Leucadia National in 2013, continues to make significant moves in... Full story

Yahoo Finance • 7 months ago

argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript May 9, 2024 argenx SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Rob and I... Full story

Yahoo Finance • 9 months ago

Harbor Capital Appreciation Fund Adjusts Portfolio, NVIDIA Corp Sees a 2.1% Impact

Insights from the Latest N-PORT Filing Reveal Strategic Investment Changes Harbor Capital Appreciation Fund (Trades, Portfolio), a prominent investment vehicle under the stewardship of Jennison Associates LLC, has recently disclosed its N... Full story

Yahoo Finance • 10 months ago

Argenx Is Tracking Well Above the Industry

Argenx SE (NASDAQ:ARGX) is a fast-growing pharmaceutical company focused on developing next-generation medicines to combat various autoimmune diseases. Investment thesis In anticipation of the release of Argenx's fourth-quarter financial... Full story

Yahoo Finance • 11 months ago

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Eur... Full story

Yahoo Finance • last year

Argenx Dives On Autoimmune Therapy Failure

Argenx dived after its antibody therapy for an autoimmune disease that causes skin blisters failed to beat a placebo in a phase 3 trial. Continue reading... Full story

Yahoo Finance • last year

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm... Full story

Yahoo Finance • last year

30 Largest Pharmaceutical Companies in the World

In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world's leading pharmac... Full story

Yahoo Finance • last year

12 Stocks Billionaire Steve Cohen Just Bought and Sold

In this article, we're going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought a... Full story

Yahoo Finance • last year

Several Catalysts Pushed argenx SE (ARGX) in Q3

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned -7.98%, A... Full story

Yahoo Finance • last year

November rally in European stocks stalls after comments from ECB officials

European shares fell for a second session on Tuesday, stalling November's strong run of gains, after European Central Bank policymakers' latest comments dampened expectations of interest rate cuts next year.... Full story

Yahoo Finance • last year

Here’s Why You Should Consider Investing in Argenx SE (ARGX)

Baron Funds, an investment management firm, released its "Baron Global Advantage Fund" third quarter 2023 investor letter, a copy of which can be downloaded here. During the third quarter of 2023, the Baron Global Advantage Fund®, denoted... Full story

Yahoo Finance • last year

argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good morning. My name is Ralph, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] Thank... Full story

Yahoo Finance • last year

Immunovant shares surge as early antibody treatment data beats expectations

Shares of Immunovant more than doubled on Tuesday after early-stage data from its experimental antibody treatment exceeded analysts' expectations.... Full story

Yahoo Finance • last year

AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease

The European Union has recommended for marketing authorization of AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizumab) for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. gMG is a rare, chronic... Full story

Yahoo Finance • 2 years ago

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine recepto... Full story

Yahoo Finance • 2 years ago

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

argenx SE Independent Data Monitoring Committee recommendedstudy continuation based onthe favorable safety profile observed in the first dose cohort Early efficacy signals support proof-of-concept of empasiprubart in multifocal motor neu... Full story

Yahoo Finance • 2 years ago

argenx announces results of Annual General Meeting of Shareholders

May3, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Mee... Full story

Yahoo Finance • 2 years ago

15 High Growth Large Cap Stocks to Invest In

In this piece, we will take a look at the 15 high growth large cap stocks to invest in. For more stocks, head on over to 5 High Growth Large Cap Stocks to Invest In. Investing in the stock market appears to be a daunting task, especially... Full story

Yahoo Finance • 2 years ago

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

March17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeti... Full story